321 related articles for article (PubMed ID: 35682890)
21. Association between effector-type regulatory T cells and immune checkpoint expression on CD8
Sato S; Matsushita H; Shintani D; Kobayashi Y; Fujieda N; Yabuno A; Nishikawa T; Fujiwara K; Kakimi K; Hasegawa K
BMC Cancer; 2022 Apr; 22(1):437. PubMed ID: 35449092
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion.
Ojasalu K; Brehm C; Hartung K; Nischak M; Finkernagel F; Rexin P; Nist A; Pavlakis E; Stiewe T; Jansen JM; Wagner U; Gattenlöhner S; Bräuninger A; Müller-Brüsselbach S; Reinartz S; Müller R
Mol Oncol; 2020 Sep; 14(9):2142-2162. PubMed ID: 32533757
[TBL] [Abstract][Full Text] [Related]
23. PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression.
Prat M; Coulson K; Blot C; Jacquemin G; Romano M; Renoud ML; AlaEddine M; Le Naour A; Authier H; Rahabi MC; Benmoussa K; Salon M; Parny M; Delord JP; Ferron G; Lefèvre L; Couderc B; Coste A
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586764
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer.
Huynh H; Teo CC; Soo KC
Mol Cancer Ther; 2007 Nov; 6(11):2959-66. PubMed ID: 18025280
[TBL] [Abstract][Full Text] [Related]
25. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers.
Burleson KM; Casey RC; Skubitz KM; Pambuccian SE; Oegema TR; Skubitz AP
Gynecol Oncol; 2004 Apr; 93(1):170-81. PubMed ID: 15047232
[TBL] [Abstract][Full Text] [Related]
26. WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer.
Kotrbová A; Ovesná P; Gybel' T; Radaszkiewicz T; Bednaříková M; Hausnerová J; Jandáková E; Minář L; Crha I; Weinberger V; Záveský L; Bryja V; Pospíchalová V
Theranostics; 2020; 10(2):537-552. PubMed ID: 31903136
[TBL] [Abstract][Full Text] [Related]
27. Targeting carcinoma-associated mesothelial cells with antibody-drug conjugates in ovarian carcinomatosis.
Pascual-Antón L; Sandoval P; González-Mateo GT; Kopytina V; Tomero-Sanz H; Arriero-País EM; Jiménez-Heffernan JA; Fabre M; Egaña I; Ferrer C; Simón L; González-Cortijo L; Sainz de la Cuesta R; López-Cabrera M
J Pathol; 2023 Oct; 261(2):238-251. PubMed ID: 37555348
[TBL] [Abstract][Full Text] [Related]
28. Flow Cytometric Analysis of Ovarian Cancer Ascites: Response of Mesothelial Cells and Macrophages to Cancer.
Hashimoto K; Honda K; Matsui H; Nagashima Y; Oda H
Anticancer Res; 2016 Jul; 36(7):3579-84. PubMed ID: 27354626
[TBL] [Abstract][Full Text] [Related]
29. Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer.
Asem M; Young A; Oyama C; ClaureDeLaZerda A; Liu Y; Ravosa MJ; Gupta V; Jewell A; Khabele D; Stack MS
Sci Rep; 2020 Jul; 10(1):11913. PubMed ID: 32681052
[TBL] [Abstract][Full Text] [Related]
30. SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells.
Xuan Y; Wang H; Yung MM; Chen F; Chan WS; Chan YS; Tsui SK; Ngan HY; Chan KK; Chan DW
Theranostics; 2022; 12(7):3534-3552. PubMed ID: 35547771
[No Abstract] [Full Text] [Related]
31. Role of malignant ascites on human mesothelial cells and their gene expression profiles.
Matte I; Lane D; Bachvarov D; Rancourt C; Piché A
BMC Cancer; 2014 Apr; 14():288. PubMed ID: 24761768
[TBL] [Abstract][Full Text] [Related]
32. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment.
Tanizaki Y; Kobayashi A; Toujima S; Shiro M; Mizoguchi M; Mabuchi Y; Yagi S; Minami S; Takikawa O; Ino K
Cancer Sci; 2014 Aug; 105(8):966-73. PubMed ID: 24826982
[TBL] [Abstract][Full Text] [Related]
33. Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids.
Correa RJ; Peart T; Valdes YR; DiMattia GE; Shepherd TG
Carcinogenesis; 2012 Jan; 33(1):49-58. PubMed ID: 22045027
[TBL] [Abstract][Full Text] [Related]
34. Tumor cell‑fibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer.
Han Q; Huang B; Huang Z; Cai J; Gong L; Zhang Y; Jiang J; Dong W; Wang Z
Int J Mol Med; 2019 Dec; 44(6):2245-2255. PubMed ID: 31638162
[TBL] [Abstract][Full Text] [Related]
35. Malignant ascites-derived exosomes promote proliferation and induce carcinoma-associated fibroblasts transition in peritoneal mesothelial cells.
Wei M; Yang T; Chen X; Wu Y; Deng X; He W; Yang J; Wang Z
Oncotarget; 2017 Jun; 8(26):42262-42271. PubMed ID: 28178689
[TBL] [Abstract][Full Text] [Related]
36. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA
Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729
[TBL] [Abstract][Full Text] [Related]
37. TGFβ signaling regulates epithelial-mesenchymal plasticity in ovarian cancer ascites-derived spheroids.
Rafehi S; Ramos Valdes Y; Bertrand M; McGee J; Préfontaine M; Sugimoto A; DiMattia GE; Shepherd TG
Endocr Relat Cancer; 2016 Mar; 23(3):147-59. PubMed ID: 26647384
[TBL] [Abstract][Full Text] [Related]
38. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
[TBL] [Abstract][Full Text] [Related]
39. Modeling Ovarian Cancer Multicellular Spheroid Behavior in a Dynamic 3D Peritoneal Microdevice.
Li SS; Ip CK; Tang MY; Sy SK; Yung S; Chan TM; Yang M; Shum HC; Wong AS
J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287578
[TBL] [Abstract][Full Text] [Related]
40. Assessment of the immune landscapes of advanced ovarian cancer in an optimized in vivo model.
Pisano S; Lenna S; Healey GD; Izardi F; Meeks L; Jimenez YS; Velazquez OS; Gonzalez D; Conlan RS; Corradetti B
Clin Transl Med; 2021 Oct; 11(10):e551. PubMed ID: 34709744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
